DSE : TECHNODRUG

Techno Drugs Ltd. — Key statistics

Pharmaceutical Preparations · Bangladesh

Last price 34.5 BDT (At close: Oct 29, 2026) · Market cap 4.55B

Latest research: Techno Drugs financial analysis: EPS down to BDT 1.51, overdue loan interest and a bond plan (Oct 2026) · Techno Drugs: FY2026 EPS of BDT 1.51 against 1.76, and BDT 129.8m of overdue loan interest disclosed in October 2026

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Technical report: trend, RSI, support and resistance, charts

Key statistics

Valuation

MeasureValue
Market Cap4.55B
Enterprise Value7.33B

Dates

MeasureValue
Earnings DateNov 8, 2026
Ex-Dividend DateNov 22, 2026

Shares

MeasureValue
Current Share Class132.00M
Shares Outstanding132.00M
Shares Change (YoY)+6.83%
Shares Change (QoQ)n/a
Owned by Insiders (%)62.72%
Owned by Institutions (%)n/a
Float49.21M

Ratios

MeasureValue
PE Ratio22.50
Forward PEn/a
PS Ratio1.47
PB Ratio1.10
P/TBV Ratio1.10
P/FCF Ration/a
P/OCF Ratio11.87
PEG Ration/a

Evratios

MeasureValue
EV / Earnings36.23
EV / Sales2.36
EV / EBITDA6.70
EV / EBIT10.62
EV / FCFn/a

Financialposition

MeasureValue
Current Ratio3.27
Quick Ratio1.37
Debt / Equity0.68
Debt / EBITDA2.57
Debt / FCFn/a
Interest Coverage1.62

Financialefficiency

MeasureValue
Return on Equity (ROE)4.98%
Return on Assets (ROA)5.77%
Return on Invested Capital (ROIC)7.87%
Return on Capital Employed (ROCE)10.22%
Weighted Average Cost of Capital (WACC)7.77%
Revenue Per Employee2.16M
Profits Per Employee140,756
Employee Count1,438
Asset Turnover0.41
Inventory Turnover1.67

Taxes

MeasureValue
Income Tax62.70M
Effective Tax Rate23.65%

Stockprice

MeasureValue
Beta (5Y)0.22
52-Week Price Change+10.58%
50-Day Moving Average39.30
200-Day Moving Average37.90
Relative Strength Index (RSI)45.04
Average Volume (20 Days)1,092,832

Shortselling

MeasureValue
Short Interestn/a
Short Previous Monthn/a
Short % of Shares Outn/a
Short % of Floatn/a
Short Ratio (days to cover)n/a

Incomestatement

MeasureValue
Revenue3.10B
Gross Profit1.35B
Operating Income690.76M
Pretax Income265.11M
Net Income202.41M
EBITDA1.07B
EBIT690.76M
Earnings Per Share (EPS)1.53

Balancesheet

MeasureValue
Cash & Cash Equivalents38.46M
Total Debt2.82B
Net Cash-2.78B
Net Cash Per Share-21.06
Equity (Book Value)4.14B
Book Value Per Share31.38
Working Capital1.99B

Cashflow

MeasureValue
Operating Cash Flow383.71M
Capital Expenditures-813.23M
Depreciation & Amortization377.22M
Net Borrowing117.68M
Free Cash Flow-429.52M
FCF Per Share-3.25

Margins

MeasureValue
Gross Margin43.66%
Operating Margin22.27%
Pretax Margin8.55%
Profit Margin6.53%
EBITDA Margin34.43%
EBIT Margin22.27%
FCF Marginn/a

Dividends

MeasureValue
Dividend Per Share1.00
Dividend Yield2.90%
Dividend Growth (YoY)n/a
Years of Dividend Growthn/a
Payout Ratio21.17%
FCF Payout Ration/a
Buyback Yield-6.83%
Shareholder Yield-3.93%
Earnings Yield4.44%
FCF Yield-9.43%

Analystforecasts

MeasureValue
Price Targetn/a
Price Target Differencen/a
Analyst Consensusn/a
Analyst Countn/a
Revenue Growth Forecast (3Y)n/a
EPS Growth Forecast (3Y)n/a

Stocksplits

MeasureValue
Last Split Daten/a
Split Typen/a
Split Ration/a

Scores

MeasureValue
Altman Z-Score2.04
Piotroski F-Score6

Fairvalue

MeasureValue
Lynch Fair Valuen/a
Lynch Upsiden/a
Graham Number
Graham Upside